A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (≥10 to <18 Years) With Type 2 Diabetes Mellitus
Phase of Trial: Phase III
Latest Information Update: 01 Aug 2018
At a glance
- Drugs Canagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Research & Development
- 03 May 2018 Planned End Date changed from 28 Jun 2021 to 30 Jun 2021.
- 23 Aug 2017 Status changed from not yet recruiting to recruiting.
- 03 Jun 2017 New trial record